The blood-brain barrier protects the brain from harmful substances, but it also prevents many medicines from reaching their ...
Recent advances in ADC development have led to increasing diversity in antibody, linker and payload design. Successful drug ...
Drug development is among the slowest, most failure-prone processes in modern science, with about 90% of drug candidates ...
Oxana Iliach is a Senior Director of Regulatory Strategy at Certara (PA, USA), a biotech company that offers comprehensive solutions for transforming and accelerating drug development. In her spare ...
As oligonucleotide therapeutics rapidly advance, their safety profile presents challenges unlike any other drug modality.
The US Food and Drug Administration (FDA) this week released a new draft guidance on the development of new drugs intended to treat pulmonary tuberculosis (TB), a bacterially-transmitted disease that ...
Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) The following represents ...
Addressing this challenge requires dedicated funding pathways that combine public support, patient capital and private-sector ...
The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results